Skip to content
LatestTopicsCompaniesFundingGlossaryAbout

Remedy Robotics raises $62M to take its remote stroke robot through an on-site trial first

DCVC led a $62 million Series B for Remedy Robotics, whose N1 robot steers catheters for stroke treatment. The money pays for an on-site pivotal trial across the University of California network; remote procedures are planned only near the end of 2027.

Robrief Newsroom
2 min readSources verified
Share

DCVC led a $62 million Series B for Remedy Robotics, the San Francisco company building the N1, a robot that steers catheters through blood vessels to treat stroke and other cardiovascular emergencies, the company said on Nov. 16. UC Investments, the University of California's investment office, joined as a new investor along with Skip Capital and Hostplus, which Remedy describes as one of Australia's largest pension funds. Build Collective, Blackbird, Divergent Capital and KdT Ventures put in more.

Remedy sells the N1 as a way to treat stroke patients wherever they are, but the round pays for the robot to prove itself with the surgeon in the room first. The money goes to a planned pivotal trial across the University of California network and work toward FDA approval for neurovascular intervention, the company said. Those first trials will be on-site elective procedures, such as treating unruptured aneurysms, IEEE Spectrum reported, and remote surgeries in Australia or within the UC system come near the end of 2027. CTO Jake Sganga called the remote version "very flashy," but said "in order to get there, we believe you have to solve a meaningful problem on-premise. Otherwise, doctors simply won't use the system."

The future trial sites are already in the deal. The University of California, which put in part of the money, will host the clinical studies within a year, according to CEO David Bell, and Remedy is placing prototype N1 systems with the Australian Stroke Alliance and SVIN Mission Thrombectomy.

Newsletter

Robrief Weekly

One email a week with the robotics news that matters. Free, unsubscribe anytime.

In patients, the farthest remote case so far was across town

Remedy's human record is small. In September 2025, a neurosurgeon in Toronto used the N1 on ten consenting patients in nonemergency procedures, IEEE Spectrum reported: six from an adjoining room, two from elsewhere in the hospital and two from a different hospital across town. The procedures, which recorded angiograms, were completed nearly twice as quickly as the current standard.

The network is the harder part of teleoperated surgery to scale. Remedy targets a round-trip latency of no more than 150 milliseconds and pauses all surgical action above it. University of Washington researcher Mike Teodorescu told IEEE Spectrum that experts usually treat 100 milliseconds as a safe threshold, and that many rural communities struggle to meet it.

The case against going slow is that the remote prize has no owner yet. No robotics company has full regulatory approval for telesurgery, and no patient has been operated on remotely in the United States, IEEE Spectrum noted, while Texas-based XCath has tested a steerable guide wire for thrombectomies in Panama. Remedy, with about 25 employees, is spending its new money on the slower route.

Sources Sources verified

  1. 1.Remedy Robotics via PR Newswire, Nov 16, 2026: Remedy Robotics Raises $62 Million Series B to Bring Life-Saving Cardiovascular Intervention to Patients Everywhereprnewswire.com
  2. 2.IEEE Spectrum, Nov 16, 2026: Can Robots Bring Stroke Surgery to Remote Hospitals?spectrum.ieee.org

Share this briefing

Know someone who follows robotics? Send it their way.

Newsletter

Robrief Weekly

One email a week with the robotics news that matters. Free, unsubscribe anytime.